Pages that link to "Q50679599"
Jump to navigation
Jump to search
The following pages link to Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial (Q50679599):
Displaying 50 items.
- Circumstances under which practice does not make perfect: a review of the practice effect literature in schizophrenia and its relevance to clinical treatment studies (Q22251051) (← links)
- Logic and justification for dimensional assessment of symptoms and related clinical phenomena in psychosis: Relevance to DSM-5 (Q22251467) (← links)
- Schizophrenia, “Just the Facts”: What we know in 2008 (Q22251476) (← links)
- Functional profile of a novel modulator of serotonin, dopamine, and glutamate neurotransmission (Q23913269) (← links)
- Perphenazine for schizophrenia (Q24187359) (← links)
- Quetiapine versus other atypical antipsychotics for schizophrenia (Q24202427) (← links)
- Quetiapine versus typical antipsychotic medications for schizophrenia (Q24202829) (← links)
- Antipsychotic drug treatment for elderly people with late-onset schizophrenia (Q24203649) (← links)
- Ziprasidone versus other atypical antipsychotics for schizophrenia (Q24240260) (← links)
- Pharmacogenetics of antipsychotic response in the CATIE trial: a candidate gene analysis (Q24600775) (← links)
- Efficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis: a systematic review and meta-analysis (Q24606868) (← links)
- Diminished orientation-specific surround suppression of visual processing in schizophrenia (Q24652714) (← links)
- Experimental treatment of antipsychotic-induced movement disorders (Q26740354) (← links)
- Current understandings about cognition and the neurobiological correlates in schizophrenia (Q26745793) (← links)
- Positive allosteric modulators of metabotropic glutamate 2 receptors in schizophrenia treatment (Q26852047) (← links)
- The cytokine model of schizophrenia: emerging therapeutic strategies (Q26865996) (← links)
- Dendritic spine pathology in schizophrenia (Q26991935) (← links)
- Update on the development of lurasidone as a treatment for patients with acute schizophrenia (Q27009585) (← links)
- Synchronizing theta oscillations with direct-current stimulation strengthens adaptive control in the human brain (Q27323969) (← links)
- Histamine H3 receptors and its antagonism as a novel mechanism for antipsychotic effect: a current preclinical & clinical perspective (Q28073102) (← links)
- Proof-of-concept trial with the neurosteroid pregnenolone targeting cognitive and negative symptoms in schizophrenia (Q28240120) (← links)
- Feasibility, safety, and efficacy of the combination of D-serine and computerized cognitive retraining in schizophrenia: an international collaborative pilot study. (Q28277784) (← links)
- Adjunctive pharmacotherapy for cognitive deficits in schizophrenia: meta-analytical investigation of efficacy (Q28297813) (← links)
- Muscarinic agonists for the treatment of cognition in schizophrenia (Q28301970) (← links)
- Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis (Q28303010) (← links)
- Oscillatory underpinnings of mismatch negativity and their relationship with cognitive function in patients with schizophrenia (Q28537683) (← links)
- Allosteric modulation of the M1 muscarinic acetylcholine receptor: improving cognition and a potential treatment for schizophrenia and Alzheimer's disease (Q28660933) (← links)
- Characterization of neurophysiologic and neurocognitive biomarkers for use in genomic and clinical outcome studies of schizophrenia (Q28727584) (← links)
- Attentional processing in C57BL/6J mice exposed to developmental vitamin D deficiency (Q28730312) (← links)
- Animal models of neuropsychiatric disorders (Q29619899) (← links)
- Effects of acute memantine administration on MATRICS Consensus Cognitive Battery performance in psychosis: Testing an experimental medicine strategy (Q30355399) (← links)
- Down-Regulation of Hippocampal Genes Regulating Dopaminergic, GABAergic, and Glutamatergic Function Following Combined Neonatal Phencyclidine and Post-Weaning Social Isolation of Rats as a Neurodevelopmental Model for Schizophrenia. (Q30368373) (← links)
- Developing treatments for cognitive deficits in schizophrenia: the challenge of translation (Q30396775) (← links)
- Neurodevelopmental animal models of schizophrenia: role in novel drug discovery and development (Q30414108) (← links)
- Evaluating the role of the alpha-7 nicotinic acetylcholine receptor in the pathophysiology and treatment of schizophrenia (Q30428422) (← links)
- Brain plasticity-based therapeutics (Q30435021) (← links)
- Too little and too much: hypoactivation and disinhibition of medial prefrontal cortex cause attentional deficits. (Q30436783) (← links)
- Reverse translation of the rodent 5C-CPT reveals that the impaired attention of people with schizophrenia is similar to scopolamine-induced deficits in mice (Q30446313) (← links)
- Cortico-subcortical neuromodulation involved in the amelioration of prepulse inhibition deficits in dopamine transporter knockout mice (Q30448782) (← links)
- Mouse pharmacological models of cognitive disruption relevant to schizophrenia (Q30457807) (← links)
- Spatial memory deficits in a virtual reality eight-arm radial maze in schizophrenia (Q30457836) (← links)
- Animal models of schizophrenia. (Q30462828) (← links)
- Using neuroplasticity-based auditory training to improve verbal memory in schizophrenia (Q30487634) (← links)
- Using the MATRICS to guide development of a preclinical cognitive test battery for research in schizophrenia (Q30489404) (← links)
- Aberrant frontoparietal function during recognition memory in schizophrenia: a multimodal neuroimaging investigation (Q30491227) (← links)
- Extrapyramidal side-effects of antipsychotics in a randomised trial (Q30492645) (← links)
- Advances in endophenotyping schizophrenia (Q30494518) (← links)
- A randomized clinical trial of MK-0777 for the treatment of cognitive impairments in people with schizophrenia (Q30498769) (← links)
- Prevention of the Phencyclidine-Induced Impairment in Novel Object Recognition in Female Rats by Co-Administration of Lurasidone or Tandospirone, a 5-HT1A Partial Agonist (Q30524240) (← links)
- Neuropsychopharmacology of auditory hallucinations: insights from pharmacological functional MRI and perspectives for future research (Q30582343) (← links)